- Home
- SLG vs PTGX Comparison
SLG vs PTGX Comparison
Compare SLG & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- PTGX
- Stock Information
- Founded
- SLG 1980
- PTGX 2006
- Country
- SLG United States
- PTGX United States
- Employees
- SLG N/A
- PTGX N/A
- Industry
- SLG Real Estate Investment Trusts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SLG Real Estate
- PTGX Health Care
- Exchange
- SLG Nasdaq
- PTGX Nasdaq
- Market Cap
- SLG 4.0B
- PTGX 4.0B
- IPO Year
- SLG 1997
- PTGX 2016
- Fundamental
- Price
- SLG $52.04
- PTGX $79.84
- Analyst Decision
- SLG Buy
- PTGX Strong Buy
- Analyst Count
- SLG 15
- PTGX 9
- Target Price
- SLG $63.00
- PTGX $78.11
- AVG Volume (30 Days)
- SLG 1.4M
- PTGX 1.6M
- Earning Date
- SLG 10-15-2025
- PTGX 10-31-2025
- Dividend Yield
- SLG 6.15%
- PTGX N/A
- EPS Growth
- SLG N/A
- PTGX N/A
- EPS
- SLG N/A
- PTGX 0.80
- Revenue
- SLG $661,814,000.00
- PTGX $209,180,000.00
- Revenue This Year
- SLG N/A
- PTGX N/A
- Revenue Next Year
- SLG $9.79
- PTGX $140.23
- P/E Ratio
- SLG N/A
- PTGX $99.17
- Revenue Growth
- SLG N/A
- PTGX N/A
- 52 Week Low
- SLG $45.15
- PTGX $33.31
- 52 Week High
- SLG $82.81
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- SLG 43.06
- PTGX 60.78
- Support Level
- SLG $49.20
- PTGX $75.44
- Resistance Level
- SLG $51.75
- PTGX $80.43
- Average True Range (ATR)
- SLG 1.65
- PTGX 2.61
- MACD
- SLG 0.09
- PTGX -0.28
- Stochastic Oscillator
- SLG 62.97
- PTGX 78.84
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.